Metformina + Vildagliptina Pharmakern (Metformin Hydrochloride, Vildagliptin)

Metformin reduces hepatic glucose production, decreases intestinal absorption of glucose, and enhances peripheral insulin sensitivity. These actions lower fasting and post‑prandial blood‑glucose concentrations without directly stimulating insulin secretion.

Vildagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4). By blocking DPP‑4, it prolongs the activity of endogenous incretin hormones (GLP‑1 and GIP), which increase glucose‑dependent insulin release and suppress glucagon secretion, thereby improving post‑prandial glucose control.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on individual factors such as renal function, glycemic targets, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Metformina + Vildagliptina Pharmakern in pregnancy and lactation are limited. The product should only be used during pregnancy or while breastfeeding if the potential benefit to the mother justifies any potential risk to the fetus or infant, and this decision must be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Adding vildagliptin to metformin provides complementary mechanisms: metformin lowers hepatic glucose output while vildagliptin enhances incretin‑mediated insulin secretion. Clinical studies show that the combination yields greater reductions in HbA1c compared with metformin monotherapy, especially in patients whose glycemic control is insufficient with metformin alone.

Store the tablets at ambient temperature below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the package.

Metformina + Vildagliptina Pharmakern tablets are taken orally, usually with meals to minimise gastrointestinal discomfort. Patients should swallow the tablet whole with a full glass of water and follow the dosing schedule prescribed by their healthcare provider.

The most critical adverse events include lactic acidosis linked to metformin, particularly in patients with renal or hepatic impairment, and severe hypersensitivity reactions such as Stevens‑Johnson syndrome associated with vildagliptin. Immediate medical attention is required if symptoms such as unexplained fatigue, abdominal pain, rash, or difficulty breathing develop.